Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Editas Medicine Inc
NASDAQ:EDIT
|
US |
|
Astronics Corp
NASDAQ:ATRO
|
US |
|
Textil Renauxview SA
BOVESPA:TXRX3
|
BR |
|
O
|
Okura Holdings Ltd
HKEX:1655
|
JP |
Balance Sheet
Balance Sheet Decomposition
Editas Medicine Inc
Editas Medicine Inc
Balance Sheet
Editas Medicine Inc
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
2
|
11
|
143
|
185
|
147
|
135
|
238
|
140
|
204
|
142
|
124
|
132
|
147
|
|
| Cash Equivalents |
2
|
11
|
143
|
185
|
147
|
135
|
238
|
140
|
204
|
142
|
124
|
132
|
147
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
183
|
234
|
219
|
262
|
296
|
203
|
199
|
138
|
0
|
|
| Total Receivables |
0
|
0
|
1
|
0
|
1
|
0
|
0
|
6
|
0
|
5
|
10
|
16
|
15
|
|
| Accounts Receivables |
0
|
0
|
1
|
0
|
1
|
0
|
0
|
6
|
0
|
5
|
10
|
16
|
15
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
2
|
2
|
6
|
6
|
11
|
7
|
7
|
8
|
3
|
2
|
|
| Total Current Assets |
2
|
11
|
145
|
187
|
332
|
375
|
464
|
419
|
507
|
357
|
341
|
289
|
164
|
|
| PP&E Net |
0
|
1
|
2
|
40
|
39
|
40
|
40
|
39
|
43
|
59
|
46
|
47
|
20
|
|
| PP&E Gross |
0
|
1
|
2
|
40
|
39
|
40
|
40
|
39
|
43
|
59
|
46
|
47
|
20
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
2
|
4
|
7
|
7
|
11
|
16
|
22
|
26
|
32
|
28
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
110
|
120
|
93
|
104
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
2
|
2
|
5
|
5
|
5
|
7
|
5
|
9
|
5
|
3
|
|
| Total Assets |
3
N/A
|
12
+388%
|
149
+1 125%
|
229
+53%
|
373
+63%
|
420
+13%
|
509
+21%
|
573
+13%
|
678
+18%
|
514
-24%
|
499
-3%
|
342
-32%
|
187
-45%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
0
|
3
|
1
|
5
|
4
|
5
|
6
|
6
|
5
|
10
|
8
|
5
|
3
|
|
| Accrued Liabilities |
1
|
2
|
6
|
17
|
11
|
13
|
28
|
31
|
31
|
42
|
47
|
61
|
39
|
|
| Short-Term Debt |
0
|
0
|
0
|
10
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
|
| Other Current Liabilities |
1
|
2
|
0
|
1
|
14
|
18
|
26
|
21
|
11
|
8
|
8
|
6
|
0
|
|
| Total Current Liabilities |
2
|
6
|
7
|
33
|
37
|
36
|
60
|
58
|
47
|
60
|
63
|
77
|
46
|
|
| Long-Term Debt |
0
|
0
|
0
|
35
|
33
|
32
|
0
|
0
|
0
|
0
|
0
|
52
|
54
|
|
| Other Liabilities |
0
|
0
|
26
|
26
|
95
|
116
|
187
|
121
|
77
|
94
|
87
|
78
|
59
|
|
| Total Liabilities |
2
N/A
|
7
+219%
|
33
+387%
|
95
+190%
|
165
+75%
|
184
+12%
|
246
+34%
|
179
-27%
|
124
-31%
|
154
+24%
|
150
-2%
|
207
+38%
|
159
-23%
|
|
| Equity | ||||||||||||||
| Common Stock |
2
|
21
|
200
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
2
|
15
|
88
|
186
|
306
|
416
|
549
|
665
|
858
|
1 078
|
1 231
|
1 468
|
1 629
|
|
| Additional Paid In Capital |
0
|
0
|
5
|
320
|
514
|
653
|
812
|
1 059
|
1 412
|
1 442
|
1 580
|
1 602
|
1 656
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
6
+1 733%
|
117
+2 024%
|
135
+15%
|
208
+55%
|
236
+14%
|
262
+11%
|
394
+50%
|
554
+41%
|
361
-35%
|
349
-3%
|
134
-62%
|
27
-80%
|
|
| Total Liabilities & Equity |
3
N/A
|
12
+388%
|
149
+1 125%
|
229
+53%
|
373
+63%
|
420
+13%
|
509
+21%
|
573
+13%
|
678
+18%
|
514
-24%
|
499
-3%
|
342
-32%
|
187
-45%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
36
|
36
|
36
|
36
|
45
|
49
|
55
|
63
|
68
|
69
|
82
|
83
|
98
|
|